Tag: M.W:500-600

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

(e) Synthesis of BRI7160 and BRI7161; The compounds were prepared according to Reaction Scheme 4: Compound 4 was prepared following the method of R. Guilard et al., Bull. Soc. Chim. Fr., 1996, 133, 65-73.A magnetically stirred suspension of compound 4 (430 mg, 0.86 mmol), (4-bromomethyl) methyl benzoate (217 mg, 0.95 mmol), KHCO3 (172 mg) and K2CO3 (174 mg) in dry acetonitrile (17 ml) was heated at reflux for 18 h under an atmosphere of nitrogen. The reaction mixture was cooled to room temperature then concentrated under reduced pressure to yield a straw coloured oil which was purified by flash chromatography (silica, 5% methanol/dichloromethane elution). Concentration of the appropriate fractions (RF 0.38) afforded adduct 5a as a clear, colourless oil. Mass Spectrum (APCI) m/z 649 [(M+H)+, 100%]., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; Prana Biotechnology Ltd; US7704987; (2010); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

To a solution of 2 (194 mg, 0.09 mmol) and 3 ( 52mg, 0.09ml) in acetonitrile (8ml), HTBU ( 34mg, 0.09 mmol) wa added followed by triethylamine ( 25 muL, 0.18mmol) at RT. the reaction was stirred for 18 h. The reaction was diluted with 30 mL dichloromethane and washed 0.1 N HCl(30 mL), 10% NaHCO3 (30 mL), brine (30 mL), then dried over MgSO4, and concentrated. The crudeproduct was purified by column chromatography (DCM:MeOH = 97:5 DCM:MeOH = 85:15) togive 4 (Figure 7) as a foam (105 mg, 43%). 1H-NMR (400 MHz, CDCl3): delta 3.68-3.47 (m, 104H,CH2OCH2CH2OCH2CH2OCH2, C3N3-NHCH2CH2CH2O , Dota-CONHCH2CH2CH2O), 3.22-3.18(br m, 8H, BocNHCH2), 1.84-1.72 (m, 28H, OCH2CH2CH2), 1.46 (s, 9H), 1.45 (s, 9H), 1.42 (s, 45H);13C-NMR (100 MHz, CDCl3) delta 176.6 (DOTA-OCOtBu), 174.4 (DOTA-OCOtBu), 172.3 (DOTA-OCOtBu),not found (C3N3), 156.0 (NHCOtBu), 81.7 (DOTA-OC(CH3)3), 78.7 (C(CH3)3), 70.47 (OCH2CH2O),70.21 (OCH2CH2O), 70.17 (OCH2CH2O), 70.10 (OCH2CH2O), 69.42 (CH2CH2CH2O), 69.02(CH2CH2CH2O), 57.5 (DOTA), 56.2 (DOTA), 55.6 (DOTA), 53.5 (DOTA), 41.9 (NH2CH2CH2CH2O),38.5 (CH2CH2CH2O), 38.4 (CH2CH2CH2O), 29.6 (NH2CH2CH2CH2O), 29.3 (NH2CH2CH2CH2O),28.4 (C(CH3)3), 27.94 (DOTA-OC(CH3)3), 27.87 (DOTA-OC(CH3)3); MS (ESI-TOF) calcd. forC127H242N27O36 2721.7936, found 2721.8117 [M + H]+. Spectra appear in the Supplementary Materials:Figures S11-S13

137076-54-1, As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Article; Lee, Changsuk; Ji, Kun; Simanek, Eric E.; Molecules; vol. 21; 3; (2016);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

A solution of the product of Example 3OB (30.0 mg, 63.8 mumol) and /-Pr2NEt (11 muL, 63 mumol) in dry DMF (1.00 mL) was transferred to a previously prepared solution of (4,7, 10-tris-f¡ãrt-butoxycarbonylmethyl- 1 ,4,7, 10-tetraazacyclododec- 1 – yl)acetic acid (47.5 mg, 82.9 mumol) in DMF (3.00 mL) containing HBTU (26.6 mg, 70.1 mumol), HOBt (10.7 mg, 69.9 mumol) and /-Pr2NEt (44 muL, 0.25 mmol); additional DMF (2 x 0.50 mL) was used to quantitate the transfer. The resulting solution was maintained at 22 C for 3 hours, then concentrated in vacuo and the residue treated with a solution OfEt3SiH in TFA (9:1 v/v, 3.30 mL). After stirring 2.5 hours at 22 0C, the resulting solution was concentrated in vacuo and purified by HPLC on a Phenomenex Luna C18 column (21.2 x 250 mm) using a 0.67%/min gradient of 0- 20% acetonitrile containing 0.1% TFA at a flow rate of 20 rnL/min. The main product peak eluting at 5.5 minutes was lyophilized to a white solid (65.0 mg, 53.6 mumol; 84.0%). MS (ESI): 643.3 (65.2, M+H), 530.3 (36.0), 322.3 (100, M+2H), 265.7 (49.7). HRMS: Calcd for C28H51N8O9: 643.3774; found: 643.3763. The optical purity of the product was established by chiral GLC analysis; 99.8% D- leucine.

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A suspension of compound 21 (1.59 g), commercially available (Aldrich Chemical Co., Milwaukee, WI) compound 22 (0.8 g) and K2CO3 (0.48 g) in DMF (15 ml) is stirred at 600C overnight. The reaction mixture is concentrated to a thick oil and filtered through a glass syringe filter, dissolved inCH2Cl2 and purified by column chromatography (silica) to give compound 23 (1.96 g)

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLYCOMIMETICS, INC.; MAGNANI, John, L.; SARKAR, Arun, K.; WO2010/126888; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

76089-77-5, Cerium(III) trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

76089-77-5, General procedure: A mixture of Ce(OTf)3 (0.1388g, 0.2mmol) and C12H8N2 (phen) (0.005g) was dissolved in a mixture of CH3CN (10ml) and DMF (three drops). After the mixture was stirred for 1h, the ligand L (0.2752g, 0.8mmol) was added to this mixture. Stirring was continued for 4h at ambient temperature. After this time, any insoluble residues were removed by filtration, and the filtrate was evaporated slowly at room temperature for about one month to yield colorless crystalline products.

The synthetic route of 76089-77-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Xu, Shan; Liu, Min; Yang, Yu-Ping; Jiang, Yu-Han; Li, Zhong-Feng; Jin, Qiong-Hua; Wang, Xin; Xue, Xiao-Nan; Polyhedron; vol. 87; (2014); p. 293 – 301;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of tri-Boc cyclam S7 (437 mg, 0.873 mmol) in anhydrous CH3CN (26 mL)were added Na2CO3 (370 mg, 3.49 mmol) and propargyl bromide (-80% in toluene, 156pL, 1 .05 mmol). The reaction mixture was heated at reflux under N2 overnight. Theinsoluble salts were filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, EtOAc:hexane =7:3) to give S11 as a white foam (446 mg, 95%). RF (EtOAc:hexane = 7:3) 0.58. m.p.47-48 C (lit.45?66 m.p. 4749 C). IR Vmax/cm1 3305, 3243, 2976, 2932, 2871, 2826,1681, 1463, 1410, 1365, 1240, 1150. 1H NMR (200 MHz, CDCI3) 5 1.40 (5, 27H, 3 xC(CH), 1.55-1.75 (m, 2H, CH2CH2CH2), 1.75-1.95 (m, 2H, CH2CH2CH2), 2.12 (5, 1H,CCH), 2.46 (t, 2H, J 5.4, CH2N(CH2CCH)CH2), 2.55-2.70 (m, 2H, CH2N(CH2CCH)CH2), 3.10-3.50 (br m, 14H, 3 x CH2N(Boc)CH2 & NCH2CCH). MS (ESI) m/z539.4 ([M+H], 100%), 561.5 ([M+Na], 28%). The spectroscopic data were inagreement with those in the literature.25?26, 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; THE UNIVERSITY OF SYDNEY; RUTLEDGE, Peter; TODD, Matthew; TRICCAS, James Anthony; WO2014/153624; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A solution of 2,6-bis(bromomethyl)quinolineS7 (63.7 mg, 200 mumol) was added to solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (101 mg, 200 mumol), bis(pyridin-2-ylmethyl)amine (40.3 mg, 200 mumol) and K2CO3 (55.9 mg, 200 mumol) in CH3CN (2.50 mL) under N2 and stirred at 80 C for 48 h under microwave irradiation. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with Na2SO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds with the mixture of regioisomers 23AB., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

76089-77-5,76089-77-5, Cerium(III) trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 7The above-described ligand represented by formula (B-13) (50 mg, 0.062 mmol) and cerium trifluoromethanesulfonate (35 mg, 0.060 mmol) were charged into a flask. Then, ethanol (5 mL) was added thereto and dissolved. The mixed solution was stirred for 2 hours at room temperature, and then the stirring was stopped. About 20 mL of diethyl ether was added, and the resultant mixture was left to stand overnight. After that, the produced solid was collected to obtain the above-described metal complex represented by composition formula (C-13) (hereinafter, ?metal complex (C-13)?). The collected amount was 41 mg (yield 43%).Elemental analysis: Found (%) C, 45.67; H, 4.71; N, 9.93; S, 6.54. Calcd for C53H62CeF9N10O9S3 (%) C, 45.78; H, 4.49; N, 10.07; S, 6.92.The metal complex (C-13) emitted a blue color in a solid powder state and in a solution state (acetonitrile) under ultraviolet excitation (365 nm).The emission spectrum in acetonitrile had a peak at 428.5 nm, the emission quantum yield was 25%, and the excitation life was 56 ns.

76089-77-5 Cerium(III) trifluoromethanesulfonate 2733941, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; SUMITOMO CHEMICAL COMPANY, LIMITED; US2012/211706; (2012); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

135616-40-9, (R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Beispiel 1 244,3 g (0.448 moi) (R, R)-2, 2 – [1, 2-CYCLOHEXANDIYL) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] (Illa) werden in 1500 ML Dichlormethan geloest und mit einer Loesung von 60,0 g (0,237 mol) Vanadylsulfat-Pentahydrat in 2000 ml Methanol versetzt. Die Reaktionsmischung ruehrt fuer 24 h bei Raumtemperatur. Anschliessend wird das Loesungsmittel abdestilliert, der Rueckstand in 1000 ml Dichlormethan aufgenommen und mit 1000 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der organischen Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 247,7 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (II) : (III) =68% : 13% : 19%. [A] D20 =-400 (c = 0,01, Chloroform). Beispiel 2 5,46 g (0.01 mol) (R, R)-2, 2 – [1, 2-CYCLOHEXANDIYL) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] (Illa) werden in 12,5 ml Dichlormethan geloest und mit einer Loesung von 1,26 g (0,005 mol) VANADYLSULFAT-PENTAHYDRAT in 12,5 ML Methanol versetzt. Die Reaktionsmischung ruehrt fuer eine Stunde bei 40 C. Anschliessend wird das Loesungsmittel abdestilliert, der Rueckstand in 50 ml Dichlormethan aufgenommen und mit 100 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der organischen Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 3,5 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (H) : (III) = 71 % : 10% : 19%.

135616-40-9, The synthetic route of 135616-40-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.76089-77-5,Cerium(III) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

76089-77-5, Cerium trifluoromethanesulfonate (0.22 g, 3.7 ¡Á 10-4mol) and ntb (0.30 g, 7.4 ¡Á 10-4 mol) were added in 100 cm3 methanol and stirred overnight under reflux. The reaction solution was filtered and left at rest. After evaporation of solvent, white fiber solid was obtained. The solid was collected by filtration and dried in vacuo. Yield: 75%. 1H NMR (DMSO-d6, 400 MHz, 298 K) delta 7.6-7.5 (q, 2H), 7.3-7.2 (q, 2H), 4.1 (s, 2H) ppm. FT-IR (ATR): 3186-2897, 1990-1623 (aromatic, comb), 1539, 1471, 1456, 1435, 1396, 1362, 1340, 1315, 1271, 1244-1171 (-CF3), 1117, 1099, 1049, 1028, 964, 935, 906, 889, 849,737, 636 cm-1. Anal. Found: C, 43.78; H, 3.27; N, 14.04%. Calcd. for C51H42CeF9N14O9S3: C,43.68; H, 3.02; N, 13.98%.

As the paragraph descriping shows that 76089-77-5 is playing an increasingly important role.

Reference£º
Article; Harada, Takashi; Hasegawa, Ryo; Nishiyama, Katsura; Chemistry Letters; vol. 43; 9; (2014); p. 1496 – 1498;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI